| Literature DB >> 29710774 |
Chih-Hua Tseng1,2,3,4, Chun-Wei Tung5,6, Shin-I Peng7, Yeh-Long Chen8, Cherng-Chyi Tzeng9, Chih-Mei Cheng10.
Abstract
The synthesis and anti-inflammatory effects of certain pyrazolo[4,3-c]quinoline derivatives 2a⁻2r are described. The anti-inflammatory activities of these derivatives were evaluated by means of inhibiting nitric oxide (NO) production in lipopolysaccharide (LPS)-induced RAW 264.7 cells. Among them, 3-amino-4-(4-hydroxyphenylamino)-1H-pyrazolo[4,3-c]-quinoline (2i) and 4-(3-amino-1H-pyrazolo[4,3-c]quinolin-4-ylamino)benzoic acid (2m) exhibited significant inhibition of LPS-stimulated NO production with a potency approximately equal to that of the positive control, 1400 W. Important structure features were analyzed by quantitative structure⁻activity relationship (QSAR) analysis to give better insights into the structure determinants for predicting the inhibitory effects on the accumulation of nitric oxide for RAW 264.7 cells in response to LPS. In addition, our results indicated that their anti-inflammatory effects involve the inhibition of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) protein expression. Further studies on the structural optimization are ongoing.Entities:
Keywords: anti-inflammatory activity; nitric oxide; pyrazolo[4,3-c]quinolines
Mesh:
Substances:
Year: 2018 PMID: 29710774 PMCID: PMC6102577 DOI: 10.3390/molecules23051036
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of pyrazolo[4,3-c]quinolines derivatives 2a–r.
The inhibitory effects of pyrazolo[4,3-c]quinoline derivatives on the accumulation of nitric oxide in the culture media of RAW 264.7 cells in response to LPS.
| Compound | a Percent Inhibition of | a IC50 ( μM) | a Cell Survival Rate at 10 μM |
|---|---|---|---|
|
| 81.66 ± 0.99 | 0.39 ± 0.08 | 9.09 ± 0.24 |
|
| 103.44 ± 6.55 | 0.42 ± 0.11 | 53.48 ± 1.53 |
|
| 82.23 ± 6.49 | 0.49 ± 0.14 | 47.31 ± 1.67 |
|
| 93.52 ± 7.57 | 0.77 ± 0.23 | 81.70 ± 0.09 |
|
| 101.43 ± 1.31 | 0.72 ± 0.18 | 94.32 ± 0.49 |
|
| 99.14 ± 2.16 | 0.29 ± 0.06 | 94.37 ± 0.36 |
|
| 103.72 ± 6.71 | 0.32 ± 0.05 | 81.61 ± 0.14 |
|
| 94.84 ± 9.47 | 0.41 ± 0.07 | 89.99 ± 0.02 |
|
| 101.72 ± 2.63 | 0.19 ± 0.05 | 87.84 ± 0.15 |
|
| 95.13 ± 3.75 | 0.92 ± 0.05 | 90.26 ± 0.05 |
|
| 90.83 ± 11.94 | 0.48 ± 0.14 | 90.57 ± 0.03 |
|
| 102.01 ± 6.49 | 0.29 ± 0.08 | 87.80 ± 0.11 |
|
| 87.68 ± 9.93 | 0.22 ± 0.07 | 85.42 ± 0.77 |
|
| 106.88 ± 2.48 | 0.36 ± 0.09 | 69.14 ± 0.62 |
|
| 100.03 ± 3.02 | 0.47 ± 0.07 | 84.53 ± 0.04 |
|
| 89.11 ± 0.86 | 0.40 ± 0.09 | 90.86 ± 0.32 |
|
| 102.29 ± 7.01 | 0.36 ± 0.08 | 89.62 ± 0.05 |
|
| 107.16 ± 2.58 | 0.35 ± 0.06 | 85.24 ± 0.04 |
| 1400w b | 102.15 ± 2.16 | 0.20 ± 0.02 | 99.54 ± 2.51 |
a Values are means ± S.D. of at least three separate experiments. b N-[[3-(Aminomethyl)-phenyl]methyl]-ethanimidamide dihydrochloride (1400W) was used as a positive control.
Figure 1NO-scavenging effects of 1400W, compounds 2i and 2m. SNP solution (2.5 mM) in PBS was incubated alone or with tested compound (10 μM) or 1400W (10 μM) in the presence of light at room temperature for 60 min.
Figure 2Inhibition of iNOS expression by 2i and 2m in LPS-stimulated RAW 264.7 cells. Cells (5 × 105 cells/well) were pretreated with the indicated concentrations of tested compounds for 2 h before incubation with 0.1 μg/mL LPS for 24 h. Cell lysates were then prepared and western blots were performed using an antibody specific for murine iNOS.
Figure 3Inhibitory effects of compound 2i and 2m on LPS-induced iNOS mRNA expression. Cells (5 × 105 cells/well) were pretreated with the indicated concentrations of tested compounds for 2 h before incubation with 0.1 μg/mL LPS for 9 h. Total RNA was prepared for RT-PCR analysis of iNOS mRNA expression in LPS-stimulated RAW 264.7 cells. GAPDH were used as internal controls for the RT-PCR assays3.4. Inhibition of LPS-inducible COX-2 expression.
Figure 4Inhibition of COX-2 expression by compound 2i and 2m in LPS-stimulated RAW 264.7 cells. Cells (5 × 105 cells/well) were pretreated with the indicated concentrations of tested compounds for 2 h before incubation with 0.1 μg/mL LPS for 24 h. Cell lysates were then prepared and western blots were performed using an antibody specific for murine COX-2.
The QSAR analysis result for pIC50 values.
| Coefficient | Estimate Std. Error | t-Value | Pr (>|t|) | ||
|---|---|---|---|---|---|
| (Intercept) | 1.258 | 0.196 | 6.42 | 3.60 × 10−4 | *** |
| SsNH2 | −0.262 | 0.017 | −15.16 | 1.30 × 10−6 | *** |
| SHBint9 | 0.049 | 0.005 | 9.21 | 3.70 × 10−5 | *** |
| nHBAcc | 0.226 | 0.038 | 5.96 | 5.60 × 10−4 | *** |
| AATSC4m | −0.037 | 0.011 | −3.46 | 1.06 × 10−2 | * |
*** p < 0.001, ** p < 0.01, * p < 0.05.
The comparison of observed and predicted values for the training dataset.
| Compound | Observed pIC50 | Predicted pIC50 | Error |
|---|---|---|---|
|
| 0.083 | 0.083 | 0.000 |
|
| 0.755 | 0.794 | −0.039 |
|
| 0.868 | 0.950 | −0.083 |
|
| 0.916 | 0.963 | −0.047 |
|
| 0.942 | 0.814 | 0.128 |
|
| 1.022 | 1.032 | −0.010 |
|
| 1.022 | 1.007 | 0.015 |
|
| 1.050 | 1.125 | −0.075 |
|
| 1.139 | 1.082 | 0.058 |
|
| 1.238 | 1.185 | 0.053 |
|
| 1.386 | 1.413 | −0.027 |
|
| 1.661 | 1.636 | 0.025 |
The comparison of observed and predicted values for the test dataset.
| Compound | Observed pIC50 | Predicted pIC50 | Error |
|---|---|---|---|
|
| 0.261 | 0.786 | −0.524 |
|
| 0.329 | 0.868 | −0.540 |
|
| 0.713 | 0.949 | −0.236 |
|
| 0.734 | 1.227 | −0.493 |
|
| 0.892 | 1.635 | −0.743 |
|
| 1.238 | 1.729 | −0.491 |
Figure 5Scatter plots of the QSAR analysis for (a) training dataset and (b) test dataset.